Corticosteroid Reduction in COPD

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

318 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-08-31

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study explores whether patients hospitalized with chronic obstructive pulmonary disease (COPD) exacerbation may have fewer days with prednisolone and with the same treatment effect by controlling the treatment by daily measurements of eosinophils.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparing Hydrocortisone and Prednisolone for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

NCT06892210

Chronic Obstructive Pulmonary Disease (COPD)

NOT_YET_RECRUITING PHASE4

Eosinophil-driven Corticotherapy for Patients Hospitalized for COPD Exacerbation

NCT04234360

COPD Exacerbation

RECRUITING PHASE3

Efficacy of Corticosteroids to Treat Outpatients With Acute Exacerbations of COPD

NCT02330952

Pulmonary Disease Chronic Obstructive (MeSH)

COMPLETED PHASE4

Steroid Resistance During COPD Exacerbations With Respiratory Failure

NCT03680495

COPD Emphysema or COPD COPD Exacerbation +3 more

UNKNOWN

The Doses of Systemic Steroid in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD)

NCT01215825

Chronic Obstructive Pulmonary Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The most commonly used treatment for acute exacerbations of chronic obstructive pulmonary disease (AECOPD) is a 5-day treatment with corticosteroids in moderate-high dose. Some patients receive repeated treatments, although it has been shown that corticosteroids only have temporary beneficial effects and no effect in relation to serious incidents or mortality. It has been found that the higher accumulated prednisolone dose disables patients due to serious side effects, including pneumonia, dysregulated diabetes, bone fracture in the context of osteoporosis, mental disorder and adrenal insufficiency etc. However, the extent of the side effects is unknown. Recent research has shown that it is presumably only a small subset of COPD patients who benefit from corticosteroid therapy. This group can be identified by the biomarker "blood-eosinophils" as already measured on most AECOPD patients during hospitalization.

This is a randomized, controlled, multi-center, non-Inferiority trial evaluating the effect of eosinophil guided corticosteroid therapy to patients with AECOPD. The aim of the study is to investigate whether the accumulated dose corticosteroid treatment during admissions for AECOPD can be reduced, including the presumed side effects, while (still) remaining the optimal treatment effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Diseases, Obstructive Blood Eosinophil Count Glucocorticoids COPD Pulmonary Disease, Chronic Obstructive

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Blood eosinophil guided prednisolone treatment

Intravenous Solu-Medrol 80 mg, followed by prednisolone tablet 37.5 mg daily (maximum of 5 days in all) if the eosinophil count in the blood ≥ 0.3 x 10E9/L. Eosinophil count in the blood \<0.3 x 10E9/L results in no treatment with prednisolone. If the patient is discharged during the treatment period, given treatment from the last measured eosinophil count the remaining days.

Group Type EXPERIMENTAL

Prednisolone

Intervention Type DRUG

Standard of care

Intravenous Solu-Medrol 80 mg on the first day followed by 37.5 mg of prednisolone tablets (1 x 25 mg plus 1 x 12.5 mg) daily for 5 days

Group Type ACTIVE_COMPARATOR

Prednisolone

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prednisolone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalized with AECOPD
* Age ≥ 40 years
* Spirometry-verified COPD (defined as FEV1 / FVC ≤ 70%)
* Chronic Obstructive Lung Disease (GOLD) class C or D
* Inclusion within 24 hours after admission

Exclusion Criteria

* Known with a diagnosis of asthma
* Life expectancy less than 30 days
* Serious exacerbation requiring invasive ventilation or admission to ICU
* Allergy to systemic corticosteroids
* Severe mental illness, which is not controlled by medication
* People who are detained under the act on the use of coercion in psychiatry
* Severe language problems or inability to provide written informed consent
* Pregnancy and lactation
* Systemic fungal infections

Minimum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No